Theraloc (nimotuzumab) for high grade glioma: the manufacturer withdrawed its marketing application

EMEA press release about the marketing authorization withdrawal for the monoclonal antibody nimotuzumab (Theraloc):

Oncoscience AG withdraws its application for Theraloc (nimotuzumab)

The European Medicines Agency (EMEA) has been formally notified by Oncoscience AG of its decision to withdraw its application for a centralised marketing authorisation for the medicine Theraloc (nimotuzumab), 5 mg/ml concentrate for solution for infusion.

Theraloc was expected to be used to treat children and adolescents with resistant or recurrent high-grade glioma. Theraloc was designated as an orphan medicine on 2 September 2004.

The application for the marketing authorisation for Theraloc was submitted to the EMEA on 4 October 2007. At the time of the withdrawal, it was under review by the Agency’s Committee for Medicinal Products for Human Use (CHMP).

In its official letter, the company stated that the withdrawal of the application was made because it was not able to adequately address the concerns of the CHMP regarding the quality and efficacy of the medicine within the required time schedule.

More information about Theraloc and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the EMEA website in due course.

Source: EMEA Press Release.  Oncoscience AG withdraws its application for Theraloc (nimotuzumab)

Illustrated Psychopharmacology Lectures in Your Inbox

  • Mechanisms of action, adverse effects and indications of psychotropic medications.
  • Concise and illustrated presentations. 
  • Practical tips for mental health professionals.




Are you a visual learner interested in learning psychopharmacology? Click here to get our videos